Skip to main content
SpringerLink
Log in

Practical implications for the administration of 13-cis retinoic acid in pediatric oncology

  • Commentary
  • Published:
International Journal of Clinical Pharmacy Aims and scope Submit manuscript

Abstract

Children with high-risk neuroblastoma are treated with polychemotherapy, surgery, radiotherapy and even autologous stem-cell transplantation. On top of this complex treatment, most children also receive 13-cis retinoic acid as differentiation agent. As no suitable pharmaceutical formulation is available so far, there are often problems with the administration of the product in children. The present report describes some practical recommendations for the administration of isotretinoin in children treated for high-risk neuroblastoma.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Maris JM. Recent advances in neuroblastoma. N Engl J Med. 2010;362(23):2202–11.

    Article  PubMed  CAS  Google Scholar 

  2. Armstrong JL, Redfern CP, Veal GJ. 13-cis retinoic acid and isomerisation in paediatric oncology—is changing shape the key to success? Biochem Pharmacol. 2005;69(9):1299–306.

    Article  PubMed  CAS  Google Scholar 

  3. E-Compendium. Scientific Leaflet Roaccutane (in Flemish). Available from URL: http:/www.ecompendium.be/. Accessed 4 Oct 2010.

  4. Matthay K, Reynolds C, Seeger R, Shimada H, Stanton Adkins E, et al. Long-term results for children with high-risk neuroblastoma treated on a randomized trial of myeloablative therapy followed by 13-cis-retinoic acid: a Children’s Oncology Group Study. J Clin Oncol. 2009;27(7):1007–13.

    Article  PubMed  CAS  Google Scholar 

  5. Veal GJ, Cole M, Errington J, Pearson A, Foot A, Whyman G, Boddy A. Pharmacokinetics and metabolism of 13-cis-retinoic acid (isotretinoin) in children with high-risk neuroblastoma—a study of the United Kingdom Children’s Cancer Study Group. Br J Cancer. 2007;96(3):424–31.

    Article  PubMed  CAS  Google Scholar 

  6. Wagner LM, Danks MK. New therapeutic targets for the treatment of high-risk neuroblastoma. J Cell Biochem. 2009;107(1):46–57.

    Article  PubMed  CAS  Google Scholar 

  7. European Medicines Agency. List of paediatric needs oncology I. Available from URL: http://www.emea.europa.eu/docs/en_GB/document_library/Other/2009/10/WC500004052.pdf. Accessed 18 Dec 2010.

  8. Priority List of Needs in Pediatric Therapeutics for 2008–2009. National institutes of child health and human development. Available from URL: http://bpca.nichd.nih.gov/about/process/upload/2009-Summary-091509.pdf. Accessed 18 Dec 2010.

  9. Colburn WA, Gibson DM, Wiens RE, Hanigan JJ. Food increases the bioavailability of isotretinoin. J Clin Pharmacol. 1983;23(11–12):534–9.

    PubMed  CAS  Google Scholar 

  10. Barnes CJ, Eichenfield LF, Lee J, Cunningham BB. A practical approach for the use of oral isotretinoin for infantile acne. Pediatr Dermatol. 2005;22(2):166–9.

    Article  PubMed  Google Scholar 

  11. Schmidt LE, Dalhoff K. Food-drug interactions. Drugs. 2002;62(10):1481–502.

    Article  PubMed  CAS  Google Scholar 

  12. Ganceviciene R, Zouboulis CC. Isotretinoin: state of the art treatment for acne vulgaris. J Dtsch Dermatol Ges. 2010;8(S1):S47–59.

    PubMed  Google Scholar 

  13. Lin HS, Leong WW, Yang JA, Lee P, Chan SY, Ho PC. Biopharmaceutics of 13-cis-retinoic acid (isotretinoin) formulated with modified beta-cyclodextrins. Int J Pharm. 2007;341(1–2):238–45.

    Article  PubMed  CAS  Google Scholar 

Download references

Funding

None.

Conflicts of interest

None.

Author information

Authors and Affiliations

  1. Department of Pediatric Hemato-Oncology, Ghent University Hospital, De Pintelaan 185, 9000, Ghent, Belgium

    Tiene G. M. Bauters, Geneviève Laureys, Véronique Van de Velde, Yves Benoit & Hugo Robays

Authors
  1. Tiene G. M. Bauters
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Geneviève Laureys
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Véronique Van de Velde
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Yves Benoit
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Hugo Robays
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Tiene G. M. Bauters.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Bauters, T.G.M., Laureys, G., Van de Velde, V. et al. Practical implications for the administration of 13-cis retinoic acid in pediatric oncology. Int J Clin Pharm 33, 597–598 (2011). https://doi.org/10.1007/s11096-011-9519-9

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11096-011-9519-9

Keywords

Search

Navigation